The European Medicines Agency (EMA) has approved this Thursday the Johnson & Johnson vaccine to deal with Covid19.

It thus becomes, after those of Pfizer, Moderna and AstraZeneca, the fourth element of the community arsenal, and

will be able to contribute up to 200 million additional doses

in the coming months.

"After a comprehensive evaluation, the EMA's Committee for Human Medicines (CHMP) has concluded by consensus that the data on the vaccine were robust and met the criteria for efficacy, safety and quality. COVID-19 Janssen is the fourth recommended vaccine in the EU to prevent COVID-19. "With this latest positive opinion, the authorities of the European Union will have another option to combat the pandemic and protect the lives and health of their citizens," said Emer Cooke, executive director of EMA. "This is the first vaccine that can be used with a single dose," he added.

The European Commission will approve, in a matter of hours, the distribution to the 27, who expect as May water a product that only requires one dose and that, in addition, allows a much simpler storage and distribution.

The news comes on the same day that Denmark has announced the interruption for two weeks of the administration of the AstraZeneca vaccine, after registering an unexpected number of thrombi among its patients.

They are not sure if there is a correlation, but they want to study it in detail.

Norway has chosen to follow in their footsteps.

The approval also coincides with

the decision of Brussels to extend, until June 30, the mechanism for the control of vaccine exports.

It has only been used once so far, to prevent 250,000 doses of AstraZeneca from leaving Italy for Australia.

But it has also served for all companies to provide data, and the result has been to verify that between February 1 and March 9, up to 34 million doses of vaccines have left the factories in Community territory, including nine million to the UK.

Nothing irregular, since they only put obstacles in the way of companies that are not complying or may breach their contracts.

The Janssen vaccine approved today provided a trial found with 44,000 people and whose results showed a 67% reduction in the number of symptomatic COVID-19 cases after two weeks in people who received the dose, an efficacy of 67%.

Furthermore, says the Amsterdam-based community body, "the side effects of the study were generally mild or moderate and disappeared within a couple of days after vaccination. The most common were injection site pain, headache, tiredness. , muscle pain and nausea. The safety and efficacy of the vaccine will continue to be monitored as it is used throughout the EU, through the EU pharmacovigilance system and additional studies conducted by the company and the European authorities. "

The EU target remains for 70% of adults to be vaccinated this summer and for everyone over 60 to achieve it before the end of May.

According to the criteria of The Trust Project

Know more

  • Covid 19

  • Coronavirus

CovidCastellón extends the cancellation of the terrace rate until December and reduce the garbage rate to the hospitality industry

Valencian Community The Valencian Community notifies 63 new deaths despite the fact that the number of infections falls to December levels

Valencian CommunityValencia will reopen children's play areas in March after the steep decline in coronavirus figures

See links of interest

  • Work calendar

  • Atlético - Athletic, live

  • PSG - Barcelona, ​​live

  • Liverpool - RB Leipzig